Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Olga M. Lapeyra, M.D.
EIR
•Olga M. Lapeyra, M.D.•October 25, 2021

Olga M. Lapeyra, M.D. – FDA EIR, Oct 25, 2021

Record Details

An FDA inspection of Olga M. Lapeyra, M.D., a clinical investigator in Miami Lakes, FL, was conducted from October 12 to October 25, 2021. This pre-announced, high-priority inspection, requested by the Center for Drug Evaluation and Research, assessed compliance with Bioresearch Monitoring standards for clinical investigators, under a specific Investigational New Drug (IND) application.

The inspection revealed two significant observations cited on an FDA Form 483. These included a failure to prepare or maintain adequate case histories with respect to observations and data pertinent to the investigation, and a failure to conduct the investigation in accordance with the investigational plan. Key issues discussed included missing protocol-required tests for three subjects, incorrect investigational product dosing for one randomized subject, inaccurate transcription of concomitant medications for four subjects, and unblinded study personnel performing tasks assigned to blinded staff. Additionally, there were instances of positive urine drug screens not adequately documented or discussed, and a subject not being re-consented with an updated informed consent form.

These findings highlight non-adherence to regulatory requirements concerning data integrity, protocol adherence, and subject protection. Dr. Lapeyra acknowledged the observations and discussed plans for staff retraining, improved source documentation practices, and clearer role definitions for unblinded personnel. She was advised to provide a written response to the FDA Form 483 within 15 business days, and received a verbal warning regarding potential regulatory actions for violations of the Food, Drug & Cosmetic Act.

Company
Olga M. Lapeyra, M.D.
Inspection date
October 25, 2021
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Matthew F. Duff (investigator)
  • Rishi Kakar (company_representative)
  • Olga M. Lapeyra (recipient)
  • Erin L. Tireman (company_representative)
View Company Profile

ID · a4978617-c36e-4ffa-8f59-5da092a97fe6

Violation Codes2
21 CFR 312.62(b)21 CFR 312.60

Full citation text and observation details available on the Dashboard.

Other documents for Olga M. Lapeyra, M.D.
  • 483 - 2024-06-07June 7, 2024
  • 483 - 2021-10-25October 25, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Olga M. Lapeyra, M.D.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.